Patents by Inventor Christian C. Fritz

Christian C. Fritz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160032387
    Abstract: Aspects and embodiments disclosed herein are directed to providing methods and systems for evaluating target genes and/or associated super enhancers and or super-enhance components. In some embodiments, the method includes selecting a gene associated with a super-enhancer, to provide a selected gene, evaluating the selected gene for contribution to a cell state, e.g., a state characterized by a disease or disorder (a disease/disorder state), and responsive to the evaluation, classifying the selected gene and/or associated super-enhancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Christian C. Fritz, David A. Orlando, Matthew G. Guenther, Jakob Loven, Peter B. Rahl, Charles Y. Lin
  • Patent number: 7851637
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: December 14, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Wei Deng, Kristopher M. Depew, Michael A. Foley, Christian C. Fritz, Asimina T. Georges Evangelinos, Michael J. Grogan, Nafeeza Hafeez, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Tao Liu, David A. Mann, Lisa A. Marcaurelle, Daniel A. Snyder, Dennis J. Underwood, Andrew A. Wylie, Lin-Chen Yu, Linping Zhang
  • Patent number: 5922856
    Abstract: The present invention provides a human cellular polypeptide, termed hRIP, that is necessary for HIV replication. The polypeptide has a molecular mass of about 59 kDa, having the sequence set forth in FIG. 2a (SEQ ID NO:1). hRIP is the cellular cofactor required to mediate the Rev response. hRIP binds HIV Rev protein and is essential for Rev activity. The invention also includes nucleic acid sequences encoding hRIP, as well as DNA vectors and transformed cells suitable for recombinant expression of this polypeptide.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: July 13, 1999
    Assignee: University of Massachusetts
    Inventors: Christian C. Fritz, Michael R. Green